Allergy Therapeutics (AGY) Competitors GBX 8.25 +0.25 (+3.13%) As of 12:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AGY vs. AMYT, APH, ANCR, VLG, DNL, EAH, STX, PXS, CHLL, and MXCShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Provexis (PXS), Chill Brands Group (CHLL), and Argent BioPharma (MXC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Its Competitors Amryt Pharma Alliance Pharma Animalcare Group Venture Life Group Diurnal Group ECO Animal Health Group Shield Therapeutics Provexis Chill Brands Group Argent BioPharma Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Does the media favor AMYT or AGY? In the previous week, Allergy Therapeutics had 2 more articles in the media than Amryt Pharma. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Allergy Therapeutics' average media sentiment score of 0.25 beat Amryt Pharma's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Amryt Pharma Neutral Allergy Therapeutics Neutral Is AMYT or AGY more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amryt PharmaN/A N/A N/A Allergy Therapeutics -72.86%-266.59%-34.76% Which has better earnings & valuation, AMYT or AGY? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmryt Pharma£210.24M0.00N/A-£33.00N/AAllergy Therapeutics£72.18M5.62-£52.59M-£1.04-7.95 SummaryAmryt Pharma beats Allergy Therapeutics on 5 of the 8 factors compared between the two stocks. Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£405.49M£2.17B£5.58B£3.01BDividend Yield8.33%2.92%5.25%5.02%P/E Ratio-7.954.1627.51149.14Price / Sales5.62555.90415.84254,247.76Price / Cash3.6610.3537.0627.97Price / Book83.6011.288.084.57Net Income-£52.59M£21.15B£3.17B£5.90B7 Day Performance3.13%1.21%3.57%7.45%1 Month Performance17.86%6.93%3.74%11.33%1 Year Performance50.00%4.23%33.78%81.11% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 8.25+3.1%N/A+56.9%£405.49M£72.18M-7.95612News CoverageAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.1626 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 295flatN/A+22.2%£202.25M£84.90M5.50220VLGVenture Life GroupN/AGBX 60.68+2.8%N/A+30.4%£77.32M£51.77M102.97165Positive NewsHigh Trading VolumeDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 58.56-2.4%N/A-52.9%£39.68M£89.44M37.86234Gap DownSTXShield TherapeuticsN/AGBX 2.89+1.4%N/A+68.4%£28.52M£20.92M-0.7440,000PXSProvexisN/AGBX 0.82-5.2%N/A+25.8%£19.24M£846.98K-31.094Positive NewsGap DownHigh Trading VolumeCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624.19K-215.007MXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap Up Related Companies and Tools Related Companies AMYT Competitors APH Competitors ANCR Competitors VLG Competitors DNL Competitors EAH Competitors STX Competitors PXS Competitors CHLL Competitors MXC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AGY) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGY Stock Alerts